fenofibrate and fluorobenzenes

fenofibrate has been researched along with fluorobenzenes in 39 studies

Research

Studies (39)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	13 (33.33)	29.6817
2010's	26 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Lin, JH; Mu, L; Prueksaritanont, T; Qiu, Y; Subramanian, R; Tang, C	1
Dane, AL; Martin, PD; Schneck, DW; Warwick, MJ	1
Tuomilehto, J	1
Durrington, PN; Hamann, A; Kallend, D; Smith, K; Tuomilehto, J	1
Arendt, CJ; Eggert, CH; Ireland, JH; Williams, AW	1
Kallem, RR; Mullangi, R; Srinivas, NR; Trivedi, RK	1
Dedhia, V; Munsi, SC	1
Elisaf, M; Gazi, IF; Kalogirou, M; Kostapanos, M; Saougos, VG; Tambaki, AP; Tselepis, AD; Wolfert, RL	1
Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC	1
Filippatos, T; Milionis, HJ	1
Awni, WM; Chira, TO; Hosmane, B; Kelly, MT; Pradhan, RS; Sleep, DJ; Stolzenbach, JC; Wan, K; Zhu, T	1
Buttler, SM; Davidson, MH; Jones, PH; Kashyap, ML; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC	1
Gratsianskiĭ, NA; Iavelov, IS; Masenko, VP; Polenova, NV; Vaulin, NA	1
Kelly, MT; Kipnes, MS; Lele, A; Rhyne, JM; Roth, EM; Setze, CM; Sleep, DJ; Stolzenbach, JC	1
Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K	1
Buyukhatipoglu, H; Dag, OF; Guntekin, U; Kirhan, I; Sezen, Y	1
Carlson, DM; Gold, A; Jones, PH; Kelly, MT; McKenney, JM; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA	1
Blasetto, JW; Carlson, DM; Fukumoto, SM; Khurmi, NS; Rosenson, RS; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA	1
Carlson, DM; Gold, A; Jacobson, TA; Kelly, MT; Pepine, CJ; Setze, CM; Stolzenbach, JC; Williams, LA	1
Carlson, DM; Hirshberg, B; Kelly, MT; Rosenson, RS; Setze, CM; Stolzenbach, JC; Williams, LA	1
Agouridis, AP; Elisaf, MS; Filippatos, TD; Tselepis, AD; Tsimihodimos, V	1
Ballantyne, CM; Jones, PH; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Thakker, KM	1
Kelly, MT; Mohiuddin, SM; Setze, CM; Thakker, KM	1
Agouridis, AP; Dimitriou, AA; Elisaf, MS; Filippatos, TD; Mikhailidis, DP; Tellis, CC; Tselepis, AD; Tsimihodimos, V	1
Bureeva, S; Hurt-Camejo, E; Kaput, J; Kleemann, R; Kooistra, T; Nikolsky, Y; Perlina, A; van Ommen, B; Verschuren, L; Wielinga, PY	1
Demonte, A; Ferreira, ES; Neves, VA; Silva, MA	1
Davidson, MH; Ferdinand, KC; Kelly, MT; Setze, CM	1
Ahn, YK; Baek, SH; Byun, YS; Cho, KI; Choi, DJ; Choi, SW; Choi, YS; Jang, Y; Jeon, DW; Kim, JY; Kim, KS; Kim, YJ; Lee, SH; Min, PK; Rha, SW	1
Rehman, HU	1
Agouridis, AP; Challa, A; Elisaf, M; Liberopoulos, EN; Makariou, SE	1
Abaigar-Luquin, P; Izquierdo-Ortiz, MJ	1
Filippatos, TD	1
Ballantyne, CM; Belmont, JW; Brautbar, A; Keinan, A; Ma, L	1
Agouridis, AP; Bairaktari, ET; Elisaf, MS; Kostapanos, MS; Kostara, C; Mikhailidis, DP; Tselepis, AD; Tsimihodimos, V	1
Elisaf, M; Kei, A; Liberopoulos, EN; Mikhailidis, DP	1
Elisaf, M; Kei, A; Liberopoulos, E; Rizzo, M; Tellis, K; Tselepis, A	1
Burns, KM; Carlson, DM; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Weinstein, DL; Williams, LA	1
Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A	2

Reviews

3 review(s) available for fenofibrate and fluorobenzenes

Article	Year
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia. Diabetes research and clinical practice, 2003, Volume: 61 Suppl 1 Topics: Body Weight; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Fluorobenzenes; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Metformin; Motor Activity; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2003
Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10 Topics: Angiography; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2008
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:3 Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2012

Trials

26 trial(s) available for fenofibrate and fluorobenzenes

Article	Year
An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clinical therapeutics, 2003, Volume: 25, Issue:2 Topics: Adult; Area Under Curve; Cross-Over Studies; Drug Interactions; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors	2003
Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes research and clinical practice, 2004, Volume: 64, Issue:2 Topics: Adult; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2004
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arteriosclerosis, thrombosis, and vascular biology, 2007, Volume: 27, Issue:10 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Azetidines; Cholesterol; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Lipoprotein(a); Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Phospholipases A2; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides	2007
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clinical drug investigation, 2008, Volume: 28, Issue:10 Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prospective Studies; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome	2008
ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. Journal of clinical pharmacology, 2009, Volume: 49, Issue:1 Topics: Adult; Cross-Over Studies; Drug Interactions; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Young Adult	2009
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis, 2009, Volume: 204, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Puerto Rico; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; United States	2009
[Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation]. Kardiologiia, 2009, Volume: 49, Issue:2 Topics: Aged; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Fluorobenzenes; Follow-Up Studies; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2009
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study. Clinical drug investigation, 2010, Volume: 30, Issue:1 Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2010
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010, Volume: 10, Issue:3 Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Humans; Hypercholesterolemia; Hypertriglyceridemia; Liver; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2010
Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:5-6 Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2010
Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. Clinical cardiology, 2010, Volume: 33, Issue:10 Topics: Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2010
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus. Cardiovascular drugs and therapy, 2011, Volume: 25, Issue:1 Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2011
High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids, 2011, Volume: 46, Issue:6 Topics: Dyslipidemias; Fatty Acids, Omega-3; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2011
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovascular drugs and therapy, 2011, Volume: 25, Issue:1 Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides	2011
Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Current medical research and opinion, 2011, Volume: 27, Issue:5 Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors	2011
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:17 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Aryldialkylphosphatase; C-Reactive Protein; Dinoprost; Drug Combinations; Dyslipidemias; Fatty Acids, Omega-3; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Inflammation; Lipids; Male; Middle Aged; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2011
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Apr-01, Volume: 12, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2012
Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia. Atherosclerosis, 2012, Volume: 221, Issue:1 Topics: Aged; Asian People; Biomarkers; Blood Glucose; Blood Urea Nitrogen; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Creatinine; Drug Combinations; Enzymes; Female; Fenofibrate; Fluorobenzenes; Hemoglobins; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Liver; Male; Middle Aged; Muscle, Skeletal; Patient Selection; Pyrimidines; Republic of Korea; Rhabdomyolysis; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome	2012
Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels. Journal of cardiovascular pharmacology and therapeutics, 2012, Volume: 17, Issue:4 Topics: 25-Hydroxyvitamin D 2; Adult; Aged; Calcifediol; Cardiovascular Diseases; Combined Modality Therapy; Dietary Supplements; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Omega-3; Female; Fenofibrate; Fluorobenzenes; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2012
Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia. Journal of lipid research, 2012, Volume: 53, Issue:11 Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angiopoietins; Apolipoproteins; Apolipoproteins B; Atorvastatin; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2012
Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. International journal of clinical practice, 2012, Volume: 66, Issue:9 Topics: Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Omega-3; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Medication Adherence; Metabolic Syndrome; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2012
Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia. International journal of clinical practice, 2013, Volume: 67, Issue:5 Topics: Cholesterol, HDL; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Niacin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2013
Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. European journal of clinical investigation, 2013, Volume: 43, Issue:7 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoproteins B; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Pilot Projects; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors	2013
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease. Clinical therapeutics, 2013, Volume: 35, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Young Adult	2013
Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions. Lipids, 2013, Volume: 48, Issue:10 Topics: Aged; Blood Chemical Analysis; Delayed-Action Preparations; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Niacin; Phospholipases A2; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2013
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia. Cardiovascular therapeutics, 2014, Volume: 32, Issue:4 Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid	2014

Other Studies

10 other study(ies) available for fenofibrate and fluorobenzenes

Article	Year
Effects of fibrates on metabolism of statins in human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals, 2002, Volume: 30, Issue:11 Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cytochrome P-450 CYP2C8; Fenofibrate; Fluorobenzenes; Gemfibrozil; Glucuronosyltransferase; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; In Vitro Techniques; Microsomes, Liver; Oxidation-Reduction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2002
Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. Annals of internal medicine, 2005, Jun-07, Volume: 142, Issue:11 Topics: Acute Kidney Injury; Female; Fenofibrate; Fluorobenzenes; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Middle Aged; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides	2005
Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study. Journal of pharmaceutical and biomedical analysis, 2005, Sep-15, Volume: 39, Issue:3-4 Topics: Acetates; Calibration; Carbamazepine; Chromatography; Chromatography, Ion Exchange; Chromatography, Liquid; Fenofibrate; Fluorobenzenes; Freezing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ions; Male; Mass Spectrometry; Models, Chemical; Pyrimidines; Quality Control; Reproducibility of Results; Rosuvastatin Calcium; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Temperature; Time Factors	2005
Myopathy caused by a combination rosuvastatin and fenofibrate. The Journal of the Association of Physicians of India, 2007, Volume: 55 Topics: Aged; Coronary Artery Disease; Drug Interactions; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Muscular Diseases; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides	2007
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010, Volume: 10, Issue:2 Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2010
Acute renal failure with the combined use of rosuvastatin and fenofibrate. Renal failure, 2010, Volume: 32, Issue:5 Topics: Acute Kidney Injury; Adult; Drug Interactions; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2010
A systems biology strategy for predicting similarities and differences of drug effects: evidence for drug-specific modulation of inflammation in atherosclerosis. BMC systems biology, 2011, Aug-12, Volume: 5 Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Cardiovascular Agents; Drug Design; Fenofibrate; Fluorobenzenes; Gene Expression Regulation; Humans; Hydrocarbons, Fluorinated; Mice; Microarray Analysis; Models, Biological; Pyrimidines; Regulatory Elements, Transcriptional; Rosuvastatin Calcium; Structure-Activity Relationship; Sulfonamides; Systems Biology	2011
β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats. Lipids in health and disease, 2012, Jan-13, Volume: 11 Topics: Animals; Anticholesteremic Agents; Antigens, Plant; Cholesterol; Diet, High-Fat; Dietary Proteins; Drug Combinations; Drug Synergism; Fenofibrate; Fluorobenzenes; Globulins; Glycine max; Heart; Hypercholesterolemia; Liver; Male; Myocardium; Organ Size; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Seed Storage Proteins; Soybean Proteins; Sulfonamides; Triglycerides	2012
The work-up for mixed hyperlipidemia: a case study. The Journal of family practice, 2012, Volume: 61, Issue:3 Topics: Adult; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Electrophoresis; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins; Male; Metformin; Physical Examination; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2012
Severe hypertriglyceridaemia. Treatment with plasmapheresis. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2012, May-14, Volume: 32, Issue:3 Topics: Acrylic Resins; Combined Modality Therapy; Fenofibrate; Filtration; Fluorobenzenes; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Molecular Weight; Plasmapheresis; Practice Guidelines as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2012